Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a single HPV shot slash cervical cancer in africa?

NCT ID NCT02834637

Vaccine Sponsor: London School of Hygiene and Tropical Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 09, 2026 · Updated 3 times

Summary

This study in Tanzania tests whether one dose of the HPV vaccine works as well as the standard two or three doses in girls aged 9-14. Cervical cancer is a major killer in East Africa, and reducing the number of shots could cut costs and make vaccination more accessible. The trial will compare immune responses from different dose schedules over several years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HPV vaccine (bivalent or nonavalent)
What this could lead to
If successful, this could show that a single dose of HPV vaccine is enough to protect against cervical cancer, making vaccination cheaper and easier to deliver in low-resource areas.
What could go wrong
This is a Phase 3 trial, but results are based on immune responses, not actual cancer prevention. Infections like malaria may affect vaccine effectiveness, and long-term protection is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

930 people

The number who actually took part.

Started

Feb 2017

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

9 to 14 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Born female; * Aged between 9 and 14 years inclusive; * Enrolled in a government primary or secondary day school in Mwanza city (or neighbouring district if included); * Living in Mwanza city (or neighbouring district if included) without plans to move away in the next 36 months; * Willing to participate in the study and sign the informed assent form; * Supported in this study participation by at least one of their parents (or LAR), who has signed the informed consent document; * In good health as determined by a medical history (a physical examination will be conducted if necessary according to the clinician's judgement); and * Able to pass a Test of Understanding (TOU) if aged 12 years or above, or if younger than 12 years old, a parent or LAR is able to pass a TOU Exclusion Criteria: * They are diagnosed with chronic conditions, such as autoimmune conditions, degenerative diseases, neurologic or genetic diseases among others; * They are HIV positive, or immunocompromised; * They are pregnant, less than three months post-partum or currently breastfeeding; * They are allergic to one of the vaccine components or to latex; * They are sexually active and are not willing to use an effective birth control method from 28 days before the first dose until 60 days after the last vaccine dose; * The nurse or clinician determining the eligibility, in agreement with principal investigator, considers that there is a reason that precludes participation; * They have been previously vaccinated against HPV

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Human papilloma virus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

human papilloma virus infection Uterine Cervical Neoplasms cervical cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Human papilloma virus

Contacts and locations

Locations

  • Mwanza Intervention Trials Unit (MITU)

    Mwanza, Tanzania

More trials for these conditions

Other studies related to the condition(s) this trial covers.